Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Research analysts at Leerink Swann issued their Q1 2018 EPS estimates for Aquinox Pharmaceuticals in a research report issued on Wednesday. Leerink Swann analyst P. Matteis expects that the company will earn ($0.68) per share for the quarter. Leerink Swann also issued estimates for Aquinox Pharmaceuticals’ Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.55) EPS.
AQXP has been the topic of several other research reports. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Needham & Company LLC restated a “buy” rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Finally, Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Aquinox Pharmaceuticals has an average rating of “Hold” and an average target price of $22.50.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $10.88 on Friday. Aquinox Pharmaceuticals has a twelve month low of $10.68 and a twelve month high of $19.97.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the last quarter. Geode Capital Management LLC grew its position in Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after acquiring an additional 11,035 shares during the last quarter. Nexthera Capital LP bought a new position in Aquinox Pharmaceuticals in the 2nd quarter valued at $1,276,000. Northern Trust Corp grew its position in Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after acquiring an additional 2,691 shares during the last quarter. Finally, Sphera Funds Management LTD. grew its position in Aquinox Pharmaceuticals by 21.7% in the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after acquiring an additional 13,450 shares during the last quarter. 95.15% of the stock is currently owned by institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.